Go Deep
Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -45,302 | -4.1 | -49.18 | 0.69 | 666.64 |
| Oct 2026 | -45,302 | -4.1 | -49.18 | 0.69 | 664.63 |
| Oct 2026 | -45,179 | -4.1 | -48.97 | 0.69 | 661.88 |
| Oct 2026 | -42,765 | -3.8 | -44.82 | 0.69 | 604.28 |
| Oct 2026 | -43,686 | -3.9 | -46.40 | 0.69 | 626.26 |
| Oct 2026 | -43,297 | -3.9 | -45.73 | 0.69 | 617.25 |
| Oct 2026 | -43,297 | -3.9 | -45.73 | 0.69 | 615.73 |
| Oct 2026 | -43,256 | -3.8 | -45.66 | 0.69 | 613.54 |
| Oct 2026 | -43,215 | -3.8 | -45.59 | 0.69 | 615.14 |
Achieve Life Sciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -74,769,000.0 | -10,168,000.0 | -14,662,000.0 | -14,441,000.0 |
| EPS | -0.8 | -0.2 | -0.3 | -0.3 |
Achieve Life Sciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -54,648,000.0 | -39,827,000.0 | -29,815,000.0 | -42,350,000.0 |
| EPS | -1.2 | -1.2 | -1.5 | -4.0 |
Achieve Life Sciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 41,790,000.0 | 38,633,000.0 | 19,371,000.0 | 29,971,000.0 | — |
| Total Liabilities | 20,272,000.0 | 17,734,000.0 | 20,819,000.0 | 21,668,000.0 | — |
| Total Equity | 21,518,000.0 | 20,899,000.0 | -1,448,000.0 | 8,303,000.0 | — |
Owes vs Owns
Achieve Life Sciences, Inc. owed $1.08 for every $1 it owned in Jun 2026, up from $0.72 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.08× | 0.49× | 0.46× | 1.07× | 0.72× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Achieve Life Sciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 87.1%Intangible assets 4.3%Other assets 8.5%
How it's funded — Dec 2025
Short-term debt 8.9%Long-term debt 26.8%Payables 2.1%Other liabilities 10.8%Shareholders' equity 51.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 36.4 | 34.3 | 15.5 | 24.7 |
| Receivables | 0.0 | 0.0 | 0.1 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.1 | 0.1 | 0.1 | 0.1 |
| Intangible assets | 1.8 | 2.0 | 2.2 | 2.5 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.6 | 2.2 | 1.5 | 2.6 |
| Liabilities & equity | ||||
| Short-term debt | 3.7 | 0.1 | 16.7 | 16.1 |
| Long-term debt | 11.2 | 9.8 | 0.0 | 0.1 |
| Payables | 0.9 | 1.9 | 0.6 | 1.7 |
| Other liabilities | 4.5 | 5.9 | 3.5 | 3.9 |
| Shareholders' equity | 21.5 | 20.9 | -1.4 | 8.3 |
| Net tangible assets | 19.7 | 18.9 | -3.7 | 5.9 |
Achieve Life Sciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -49,465,000.0 | -29,770,000.0 | -24,479,000.0 | -37,569,000.0 | — |
| Investing Activities | 6,111,000.0 | -21,580,000.0 | -21,000.0 | 0.0 | — |
| Financing Activities | 51,527,000.0 | 48,527,000.0 | 15,278,000.0 | 19,315,000.0 | — |